Impact of main branch selection on clinical outcomes after percutaneous coronary intervention for unprotected left main coronary artery disease: a substudy from the DELTA registry.

Emanuele Meliga1, Ottavio Alfieri1, Marta Bande1, Pawel E. Bazan1, Tiziano Chakravarty1, Aisata Chieffo2, Antonio Colombo3, Maria Rosa Conte4, Mauro De Benedictis5, Andrea Ereli6, Jean Fajadet7, Sandra Jegere7, Azem Lati11, Thierry Leferve7, Martin Leon8, Raj Makkar9, Rosana Mehran10, Marie-Claude Morice12, Jeffrey W. Moses13, Christoph Naber14, Yoshinobu Onuma15, Igor Palacios16, Seung-Jung Park17, Innocenzo Scrocca18, Patrick W. Serruys19, Corrado Tamburino20
1Mauriziano Umberto I Hospital, Turin, Italy, 2San Raffaele Scientific Institute, Milan, Italy, 3I.R.C.C.S. Policlinico San Donato, San donato milanese, Italy, 4Medical University of Silesia, Katowice, Katowice, Poland, 5Cedars Sinai Medical Center, Los Angeles, CA, 6San Raffaele Scientific Institute, Milan, Italy, 7EMO GVM Centro Cuore ColumbusSan Raffaele Hospital, Milan, Italy, 8Mauriziano Umberto I hospital, turin, Italy, 9Mauriziano Hospital, Turin, Italy, 10Pauls Stradins Clinical University Hospital, Riga, Latvia, 11CLINIQUE PASTEUR, Toulouse, France, 12Pauls Stradins Clinical University Hospital, Riga, Not applicable, 13ICPMS, France, 14Cardiovascular Research Foundation, New York, NY, 15Associate Prof, UCLA school of Medicine, Los Angeles, California, 16Mount Sinai Hospital, New York, NY, 17Institut Cardiovasculaire Paris Sud, Massy, France, 18Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 19Torino Heart and Vascular Center, Elisabeth Krankenhaus Essen, Germany, 20ThoraxCenter, Rotterdam, Rotterdam, 21MASS General Hospital, Boston, MA, 22Asan Medical Center, Seoul, Korea, Republic of, 23Ospedale Mauriziano, TORINO, Italy, 24Thoraxcenter-Erasmus University, Rotterdam, Netherlands, 25University of Catania, Catania, Italy

Background: In the setting of PCI for ULMCA disease, left anterior descending artery (LAD) is generally considered the main branch. However, whether the choice of LAD over LCX as main branch has a significant impact on clinical outcomes has not yet been ascertained.

Methods: Between April 2002 and April 2006, a total of 2775 patients were included in the DELTA registry. 1,874 were treated with PCI vs. 901 with CABG. Of the percutaneous group, we selected only those patients who had distal left main disease and complete information about stenting technique. After 1:1 propensity-score matching was performed, matched pairs of patients were selected and analyzed.

Results: In total 276 patients were included in the analysis: in 138 cases the selected main branch was the LAD (LM-LAD) and in 138 cases was the LCX (LM-LCX). Clinical, angiographic and procedural characteristics in the matched groups were similar. Mean EuroSCORE and SyntaxSCORE in the LM-LAD and LM-LCX groups were 5.3 vs 5.5 (p = 0.34) and 29.7 vs 28.9; 10 (p = 0.56). Incidence of adverse events at follow-up (median: 1098 days; IQR 936-1478) are reported in Table 1. MACCE-free survival rate in the LM-LAD vs LM-LCX groups at 1478 days was 60.4 vs. 51.2 (p = 0.03). No significant advantage of the LM-LAD subgroup in terms of death, TLR, TVR and MACCE was confirmed in patients who were treated with a 2 stent technique while no difference between groups was found when a single stent strategy was considered.

Conclusions: In this series of matched patients with ULMCA disease, the choice of LAD over LCX as main branch was correlated with a significantly lower incidence of death, TLR, TVR and MACCE at long term FU. This advantage was substantial when a two stent strategy was considered.

Impact of main branch selection on clinical outcomes after percutaneous coronary intervention for unprotected left main coronary artery disease: a substudy from the DELTA registry.

Emanuele Meliga1, Ottavio Alfieri1, Marta Bande1, Pawel E. Bazan1, Tiziano Chakravarty1, Aisata Chieffo2, Antonio Colombo3, Maria Rosa Conte4, Mauro De Benedictis5, Andrea Ereli6, Jean Fajadet7, Sandra Jegere7, Azem Lati11, Thierry Leferve7, Martin Leon8, Raj Makkar9, Rosana Mehran10, Marie-Claude Morice12, Jeffrey W. Moses13, Christoph Naber14, Yoshinobu Onuma15, Igor Palacios16, Seung-Jung Park17, Innocenzo Scrocca18, Patrick W. Serruys19, Corrado Tamburino20
1Mauriziano Umberto I Hospital, Turin, Italy, 2San Raffaele Scientific Institute, Milan, Italy, 3I.R.C.C.S. Policlinico San Donato, San donato milanese, Italy, 4Medical University of Silesia, Katowice, Katowice, Poland, 5Cedars Sinai Medical Center, Los Angeles, CA, 6San Raffaele Scientific Institute, Milan, Italy, 7EMO GVM Centro Cuore ColumbusSan Raffaele Hospital, Milan, Italy, 8Mauriziano Umberto I hospital, turin, Italy, 9Mauriziano Hospital, Turin, Italy, 10Pauls Stradins Clinical University Hospital, Riga, Latvia, 11CLINIQUE PASTEUR, Toulouse, France, 12Pauls Stradins Clinical University Hospital, Riga, Not applicable, 13ICPMS, France, 14Cardiovascular Research Foundation, New York, NY, 15Associate Prof, UCLA school of Medicine, Los Angeles, California, 16Mount Sinai Hospital, New York, NY, 17Institut Cardiovasculaire Paris Sud, Massy, France, 18Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, 19Cornell Heart and Vascular Center, Elisabeth Krankenhaus Essen, Germany, 20ThoraxCenter, Rotterdam, Rotterdam, 21MASS General Hospital, Boston, MA, 22Asan Medical Center, Seoul, Korea, Republic of, 23Ospedale Mauriziano, TORINO, Italy, 24Thoraxcenter-Erasmus University, Rotterdam, Netherlands, 25University of Catania, Catania, Italy

Background: In the setting of PCI for ULMCA disease, left anterior descending artery (LAD) is generally considered the main branch. However, whether the choice of LAD over LCX as main branch has a significant impact on clinical outcomes has not yet been ascertained.

Methods: Between April 2002 and April 2006, a total of 2775 patients were included in the DELTA registry. 1,874 were treated with PCI vs. 901 with CABG. Of the percutaneous group, we selected only those patients who had distal left main disease and complete information about stenting technique. After 1:1 propensity-score matching was performed, matched pairs of patients were selected and analyzed.

Results: In total 276 patients were included in the analysis: in 138 cases the selected main branch was the LAD (LM-LAD) and in 138 cases was the LCX (LM-LCX). Clinical, angiographic and procedural characteristics in the matched groups were similar. Mean EuroSCORE and SyntaxSCORE in the LM-LAD and LM-LCX groups were 5.3 vs 5.5 (p = 0.34) and 29.7 vs 28.9; 10 (p = 0.56). Incidence of adverse events at follow-up (median: 1098 days; IQR 936-1478) are reported in Table 1. MACCE-free survival rate in the LM-LAD vs LM-LCX groups at 1478 days was 60.4 vs. 51.2 (p = 0.03). When stratified by stent strategy (1 vs 2 stent technique), the significant advantage of the LM-LAD subgroup in terms of death, TLR, TVR and MACCE was confirmed in patients who were treated with a 2 stent technique while no difference between groups was found when a single stent strategy was considered.

Conclusions: In this series of matched patients with ULMCA disease, the choice of LAD over LCX as main branch was correlated with a significantly lower incidence of death, TLR, TVR and MACCE at long term FU. This advantage was substantial when a two stent strategy was considered.